Lower motor neuron syndrome with late-adult onset

disease
On this page

Also known as SMAJspinal muscular atrophy, Jokela type

Summary

Lower motor neuron syndrome with late-adult onset (MONDO:0014025) is a disease caused by CHCHD10 (GenCC Strong), with 2 cohort genes.

At a glance

  • Prevalence: <1 / 1 000 000 (Worldwide) [Orphanet-validated]
  • Causal gene: CHCHD10 (GenCC Strong)
  • Cohort genes: 2
  • ClinVar variants: 222
  • Phenotypes (HPO): 26

Clinical features

Epidemiology

Prevalence records

2 prevalence record(s), Orphanet:

TypeClassValueGeographyValidation
Cases/families55WorldwideValidated
Point prevalence<1 / 1 000 000WorldwideValidated

Signs & symptoms

Clinical features (HPO)

26 HPO clinical features (Orphanet curated; top 26 by frequency):

HPO IDTermFrequency
HP:0009053Distal lower limb muscle weaknessVery frequent (80-99%)
HP:0001265HyporeflexiaFrequent (30-79%)
HP:0001284AreflexiaFrequent (30-79%)
HP:0001288Gait disturbanceFrequent (30-79%)
HP:0002380FasciculationsFrequent (30-79%)
HP:0003236Elevated circulating creatine kinase concentrationFrequent (30-79%)
HP:0003445EMG: neuropathic changesFrequent (30-79%)
HP:0003449Cold-induced muscle crampsFrequent (30-79%)
HP:0003710Exercise-induced muscle crampsFrequent (30-79%)
HP:0008985Increased intramuscular fatFrequent (30-79%)
HP:0008994Proximal muscle weakness in lower limbsFrequent (30-79%)
HP:0031921Gastrocnemius myalgiaFrequent (30-79%)
HP:0001308Tongue fasciculationsOccasional (5-29%)
HP:0001337TremorOccasional (5-29%)
HP:0002015DysphagiaOccasional (5-29%)
HP:0003200Ragged-red muscle fibersOccasional (5-29%)
HP:0003458EMG: myopathic abnormalitiesOccasional (5-29%)
HP:0003805Rimmed vacuolesOccasional (5-29%)
HP:0006886Impaired distal vibration sensationOccasional (5-29%)
HP:0008954Intrinsic hand muscle atrophyOccasional (5-29%)
HP:0008997Proximal muscle weakness in upper limbsOccasional (5-29%)
HP:0040132Abnormal sensory nerve conduction velocityOccasional (5-29%)
HP:0002493Upper motor neuron dysfunctionExcluded (0%)
HP:0002086Abnormality of the respiratory systemVery rare (<1-4%)
HP:0002483Bulbar signsVery rare (<1-4%)
HP:0002540Inability to walkVery rare (<1-4%)

Identifiers

Disease identifiers

FieldValue
Canonical namelower motor neuron syndrome with late-adult onset
Mondo IDMONDO:0014025
OMIM615048
Orphanet276435
DOIDDOID:0081356
ICD-111650555742
UMLSC3554398
MedGen767312
GARD0017282
Is cancer (heuristic)no

Also known as: SMAJ · spinal muscular atrophy, Jokela type

Data availability: 222 ClinVar variants · 3 GenCC gene-disease records.

Disease family

Classification path: disease › human disease › disease by body system or component › nervous system disordercentral nervous system disorderspinal cord disorderanterior horn disorderspinal muscular atrophyproximal spinal muscular atrophylower motor neuron syndrome with late-adult onset

Related subtypes (5): spinal muscular atrophy, type 1, spinal muscular atrophy, type III, spinal muscular atrophy, type II, spinal muscular atrophy, type IV, autosomal dominant childhood-onset proximal spinal muscular atrophy

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

222 retrieved; paginated sample, class counts are floors:

116 uncertain significance, 78 likely benign, 11 conflicting classifications of pathogenicity, 8 benign/likely benign, 6 benign, 2 pathogenic, 1 pathogenic/likely pathogenic

ClinVarVariant (HGVS)GeneClassificationReview
1452852NM_213720.3(CHCHD10):c.44_45delinsTT (p.Arg15Leu)CHCHD10Pathogeniccriteria provided, single submitter
180220NM_213720.3(CHCHD10):c.44G>T (p.Arg15Leu)CHCHD10Pathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
180221NM_213720.3(CHCHD10):c.197G>T (p.Gly66Val)CHCHD10Pathogeniccriteria provided, single submitter
1080264NM_213720.3(CHCHD10):c.42-5C>TCHCHD10Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
1446575NM_213720.3(CHCHD10):c.42-5C>GCHCHD10Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
204292NM_213720.3(CHCHD10):c.239C>T (p.Pro80Leu)CHCHD10Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
2061695NM_213720.3(CHCHD10):c.261+10_261+11delinsAGCHCHD10Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
2922669NM_213720.3(CHCHD10):c.215C>T (p.Ala72Val)CHCHD10Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
473421NM_213720.3(CHCHD10):c.214G>A (p.Ala72Thr)CHCHD10Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
540611NM_213720.3(CHCHD10):c.274G>A (p.Ala92Thr)CHCHD10Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
565755NM_213720.3(CHCHD10):c.312C>G (p.Tyr104Ter)CHCHD10Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
567906NM_213720.3(CHCHD10):c.276T>A (p.Ala92=)CHCHD10Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
640736NM_213720.3(CHCHD10):c.224G>A (p.Gly75Glu)CHCHD10Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
655998NM_213720.3(CHCHD10):c.196G>A (p.Gly66Ser)CHCHD10Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
665651NC_000022.10:g.(?24108011)(24110169_?)dupC22orf15Uncertain significancecriteria provided, single submitter
831034NC_000022.11:g.(?23765824)(23767603_?)delC22orf15Uncertain significancecriteria provided, single submitter
1000426NM_213720.3(CHCHD10):c.2T>G (p.Met1Arg)CHCHD10Uncertain significancecriteria provided, single submitter
1003466NM_213720.3(CHCHD10):c.8G>C (p.Arg3Pro)CHCHD10Uncertain significancecriteria provided, single submitter
1021740NM_213720.3(CHCHD10):c.235G>A (p.Glu79Lys)CHCHD10Uncertain significancecriteria provided, single submitter
1026524NM_213720.3(CHCHD10):c.409+1G>ACHCHD10Uncertain significancecriteria provided, multiple submitters, no conflicts
1036655NM_213720.3(CHCHD10):c.263C>A (p.Ala88Asp)CHCHD10Uncertain significancecriteria provided, single submitter
1040911NM_213720.3(CHCHD10):c.55C>T (p.Pro19Ser)CHCHD10Uncertain significancecriteria provided, single submitter
1043025NC_000022.10:g.(?24109541)(24110081_?)delCHCHD10Uncertain significancecriteria provided, single submitter
1043375NM_213720.3(CHCHD10):c.42-2A>GCHCHD10Uncertain significancecriteria provided, single submitter
1052112NM_213720.3(CHCHD10):c.302C>T (p.Pro101Leu)CHCHD10Uncertain significancecriteria provided, single submitter
1313416NM_213720.3(CHCHD10):c.211G>A (p.Gly71Arg)CHCHD10Uncertain significancecriteria provided, multiple submitters, no conflicts
1352828NM_213720.3(CHCHD10):c.350G>A (p.Ser117Asn)CHCHD10Uncertain significancecriteria provided, single submitter
1387504NM_213720.3(CHCHD10):c.308C>T (p.Ala103Val)CHCHD10Uncertain significancecriteria provided, single submitter
1388815NM_213720.3(CHCHD10):c.10G>C (p.Gly4Arg)CHCHD10Uncertain significancecriteria provided, multiple submitters, no conflicts
1394238NM_213720.3(CHCHD10):c.389A>G (p.Lys130Arg)CHCHD10Uncertain significancecriteria provided, single submitter

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 10 · Orphanet: 4 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

GeneClassificationInheritanceDiseaseRecords
CHCHD10StrongAutosomal dominantlower motor neuron syndrome with late-adult onset10

Orphanet rare-disease linkage (cohort genes)

GeneOrphanet IDRare disease
CHCHD10Orphanet:275872Frontotemporal dementia with motor neuron disease
CHCHD10Orphanet:276435Lower motor neuron syndrome with late-adult onset
CHCHD10Orphanet:457050Autosomal dominant mitochondrial myopathy with exercise intolerance
CHCHD10Orphanet:803Amyotrophic lateral sclerosis

Cohort genes → proteins

2 cohort genes, 2 distinct canonical proteins.

Evidence partition

SubsetGenes
multi_evidence2

Cohort genes (full)

SymbolHGNCEnsemblUniProtNameEvidence
CHCHD10HGNC:15559ENSG00000250479Q8WYQ3Coiled-coil-helix-coiled-coil-helix domain-containing protein 10, mitochondrialgencc,clinvar
C22orf15HGNC:15558ENSG00000169314Q8WYQ4Uncharacterized protein C22orf15clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

SymbolProtein nameFunction (lead sentence)
CHCHD10Coiled-coil-helix-coiled-coil-helix domain-containing protein 10, mitochondrialMay be involved in the maintenance of mitochondrial organization and mitochondrial cristae structure.

Protein-family classification

Druggable: 0 · Difficult: 0 · Unknown: 2 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

FamilyGenesFoldFDR
Other/Unknown21.8×0.312

Per-gene assignment

SymbolFamilyDruggable?ECInterPro (top 3)
CHCHD10Other/UnknownnoCHCH, CHCHD2/10-like
C22orf15Other/UnknownnoCXorf65-like

Expression context

Cohort genes with no expression data: 0.

2 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

BucketGenes
narrow (1-5 tissues)0
moderate (6-20)0
broad (>20)2
unknown0

Top tissues across cohort

TissueCohort genes
apex of heart1
heart left ventricle1
hindlimb stylopod muscle1
male germ line stem cell (sensu Vertebrata) in testis1
olfactory segment of nasal mucosa1
right uterine tube1

Per-gene tissue summary (top 30)

SymbolBgee breadthFANTOM5 breadthSCXATop tissues
CHCHD10133ubiquitousmarkerapex of heart, heart left ventricle, hindlimb stylopod muscle
C22orf15123markerright uterine tube, olfactory segment of nasal mucosa, male germ line stem cell (sensu Vertebrata) in testis

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

SymbolInteractor count
CHCHD101,344
C22orf15152

Structural data

PDB: 1 · AlphaFold-only: 1 · No structure: 0

Cohort genes with PDB structures (top 30)

SymbolUniProtPDB entries
CHCHD10Q8WYQ35

AlphaFold-only cohort genes (top 30 by pLDDT)

SymbolUniProtpLDDT
C22orf15Q8WYQ476.10

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 1. Enrichment computed across 2 evidence-associated genes (1 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

PathwayCohort genesFoldFDRSample cohort genes
Mitochondrial protein import1167.9×0.006CHCHD10

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO termCohort genesFoldFDRSample cohort genes
mitochondrial membrane organization12407.4×0.001CHCHD10
inner mitochondrial membrane organization1842.6×0.002CHCHD10
mitochondrion organization1151.8×0.007CHCHD10

Therapeutics

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 2

Druggability breadth: 0 of 2 evidence-associated genes (0%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

SymbolMoleculesMax phase
CHCHD1000
C22orf1500

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Pharmacogenomics

Cohort genes with a PharmGKB record: 2; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

TierDefinitionGenesSymbols
AApproved (phase 4 drug)0
BPhased (≥1) drug, not yet approved0
CDruggable family + PDB, no drug0
DDruggable family + AlphaFold only, no drug0
EDifficult family or no structure, no drug2CHCHD10, C22orf15

Undrugged target profiles

2 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

SymbolChEMBL assaysDrugged partners (top 3)
CHCHD100
C22orf150

Clinical trials & evidence

Clinical trials

Clinical trials: 0.